Navigation Links
Vr Laboratories Selects Hsg2001 As Lead Development Candidate For Candida Albicans Program
Date:11/16/2012

Bonita Springs, Fla., Nov. 16, 2012 /PRNewswire-iReach/ -- VR Laboratories LLC today announced they have selected a lead product candidate based on preclinical activity to target Candida albicans (C. albicans). C. albicans is the most common yeast species that causes candidiasis, commonly referred to as yeast infections. Candidiasis includes topical infections such as thrush as well as systemic and potentially life-threatening invasive diseases.

(Photo: http://photos.prnewswire.com/prnh/20121116/CG15396)

Three of every four women experience at least one bout of candidiasis in their lifetime and many experience recurrent infections. Symptoms of candidiasis vary depending on the area of the body that is infected. Candidiasis can be severe and causes more fatalities than any other systemic fungal infection. Candida species are the most common cause of fungal infections in immunocompromised patients such as cancer, AIDS, and transplant patients.

HSG2001 is an orally administered and bioavailable product that prevents the growth of C. albicans in vitro. Preclinical data suggests the product could be used alone or in combination with known antifungals.

"We searched our industry leading natural product library and identified HSG2001 as our lead candidate based on its ability to inhibit C. albicans growth in early stage testing." said Jeff Kottkamp, CEO of VR Laboratories. "We are very excited to expand the utilization of our knowledge and proprietary technology into discovering potential natural medicines for diseases with high unmet medical needs."

About VR Laboratories

VR Laboratories is an innovative natural products company formed by industry professionals in 2010 to be the leading global formulator and producer of natural products.  VR Laboratories utilizes industry-changing proprietary technology to create, produce and market "First in Class" condition specific botanical based consumer health and wellness products, FDA-approved botanical pharmaceuticals and medicines, and proprietary ingredients for medicinal and functional foods and beverages. The company utilizes a proprietary technology platform created by HerbalScience, which has fully developed more than 1,000 medicinal and functional ingredients.  VR Laboratories is headquartered in Bonita Springs, Florida.


'/>"/>
SOURCE VR Laboratories www.vr-laboratories.com
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ameritox Files Amended Complaint Against Millennium Laboratories For Injunctive Relief, Declaratory Relief and Damages
2. Millennium Laboratories Sponsors Educational Programs in Support of Safe Prescribing Practices at Regional Pain Society Conferences
3. Grant & Eisenhofer Represents Lead Whistleblower in Historic $1.6 Billion Settlement with Abbott Laboratories Over Off-Label Marketing of Antiepileptic Medication Depakote
4. Dave Zitnak Of Upsher-Smith Laboratories Named Branded Representative Of The Year By McKesson Corporation
5. New Data Support Role of Prometheus Laboratories Novel Assay in Optimizing IBD Treatment Management
6. Everett Laboratories, Inc. Files Patent Infringement Lawsuit Against Competitor Trigen Laboratories, Inc.
7. PeaceHealth Laboratories New Patent Addresses a Leading Cause of Death: Prescription Drug Abuse
8. Omega Laboratories Applauds the Adoption of Enzyme Immunoassay (EIA) by Major Hair Testing Laboratories
9. Court Preliminarily Deems Millennium Laboratories Press Release Misleading
10. Millennium Laboratories Wins Lawsuit: Ameritox Advertisements Regarding Rx Guardian and Rx Guardian CD Contain Literally False Statements
11. Carl Icahn Issues Letter To Howard Solomon Of Forest Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... -- Novavax, Inc., (Nasdaq: NVAX ) today announced that ... its RSV F protein recombinant nanoparticle vaccine candidate (RSV F ... in the journal Vaccine (the data ... conferences). The Company previously announced top line results ... RSV F Vaccine with the goal of protecting infants from ...
(Date:6/5/2017)... , June 5, 2017 The ... brand of Diplomat Pharmacy, Inc. (NYSE: DPLO), has been awarded ... Cincinnati Enquirer . Results are based on an ... in organizational health and workplace improvement. The survey measures several ... ...
(Date:6/3/2017)... , June 3, 2017  Eli Lilly and ... that results from the Phase 3 MONARCH 2 ... & 6 inhibitor, in combination with fulvestrant, significantly ... fulvestrant alone in women with hormone-receptor-positive (HR+), human ... cancer who have relapsed or progressed after endocrine ...
Breaking Medicine Technology:
(Date:6/26/2017)... RU (PRWEB) , ... June 26, 2017 , ... ... released a whitepaper that pledges to solve many catastrophic issues within funding campaigns. ... 2017. , The typical notion of crowdfunding - the raising of funds through the ...
(Date:6/25/2017)... ... ... FCPX LUT Vintage Volume 2 for Final Cut Pro X allows users ... contains 60 different color-grade presets, giving editors multiple options for adding different color options. ... subjects, plus much more. FCPX LUT Vintage Volume 2 is designed for any skill-set ...
(Date:6/25/2017)... ... ... Republicans in the United States Senate on Thursday released their version of ... differs significantly from the American Health Care Act, which the House passed in May, ... will have to take up the Senate version as-is, if it passes. , The ...
(Date:6/25/2017)... ... , ... CareSet Labs released the Root NPI Graph today at the 2017 ... improved version of the Doctor Referral teaming dataset commonly available from Medicare. , Originally ... the the “Doctor Referral Dataset” as released by Medicare and “DocGraph” as released by ...
(Date:6/25/2017)... ... 2017 , ... June is Men’s Health Month and the focus is on prostate ... in the U.S. and the third most common cause of cancer related death today; lung ... seven will be diagnosed with prostate cancer during his lifetime. Those at highest risk ...
Breaking Medicine News(10 mins):